For the year ending 2025-12-31, JAGX made $11,511K in revenue. -$53,941K in net income. Net profit margin of -468.60%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue, net | 11,511 | 11,689 | ||
| Cost of product revenue | 3,774 | 1,955 | ||
| Research and development | 24,966 | 16,542 | ||
| Sales and marketing | 9,235 | 7,692 | ||
| General and administrative | 18,644 | 16,331 | ||
| Impairment loss on indefinite-lived intangible assets | 800 | - | ||
| Total operating expenses | 57,419 | 42,520 | ||
| Loss from operations | -45,908 | -30,831 | ||
| Changes in fair value of freestanding and hybrid financial instruments designated at fair value option | 6,266 | 9,485 | ||
| Gain (loss) on extinguishment of debt | -1,799 | 1,245 | ||
| Interest income (expense) | 67 | 231 | ||
| Other income (expense) | 43 | 51 | ||
| Loss before income tax expense | -53,997 | -39,251 | ||
| Income tax expense | 0 | - | ||
| Net loss | -53,997 | -39,251 | ||
| Net loss attributable to noncontrolling interest | -563 | -759 | ||
| Deemed dividend to preferred stockholders | 141 | - | ||
| Net loss attributable to common stockholders | -53,575 | - | ||
| Translation adjustments | -366 | - | ||
| Net loss attributable to common stockholders | - | -38,492 | ||
| Net comprehensive loss attributable to common stockholders | -53,941 | - | ||
| Basic EPS | -22.97 | -130.69 | ||
| Diluted EPS | -22.97 | -130.69 | ||
| Basic Average Shares | 2,332,401 | 294,534 | ||
| Diluted Average Shares | 2,332,401 | 294,534 | ||
Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc. (JAGX)